Shopping Cart
Remove All
Your shopping cart is currently empty
JMV 2959 hydrochloride (925238-89-7 free base) is a growth hormone secretagogue receptor type 1a (GHS-R1a) antagonist with an IC50 of 32±3 nM in LLC-PK1 cells.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $35 | In Stock | In Stock | |
| 5 mg | $81 | In Stock | In Stock | |
| 10 mg | $129 | In Stock | In Stock | |
| 25 mg | $277 | In Stock | In Stock | |
| 50 mg | $412 | In Stock | In Stock | |
| 100 mg | $588 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $98 | In Stock | In Stock |
| Description | JMV 2959 hydrochloride (925238-89-7 free base) is a growth hormone secretagogue receptor type 1a (GHS-R1a) antagonist with an IC50 of 32±3 nM in LLC-PK1 cells. |
| Targets&IC50 | GHS-R1a:32±3 nM (in LLC-PK1 cells) |
| In vitro | JMV 2959 does not induce any intracellular calcium mobilization by itself. The dissociation constant of the receptor/JMV 2959 complex is determined by the Schild method. This experiment reveals a dissociation constant Kb of 19±6 nM.JMV 2959 is a growth hormone secretagogue receptor type 1a (GHS-R1a) antagonist with an IC50 of 32 nM. |
| In vivo | Intraperitoneal (i.p.) administration of Ghrelin at doses of 0.033, 0.1, and 0.33 mg/kg does not significantly affect acoustic startle responses (ASR) or prepulse inhibition (PPI) in rats. Conversely, i.p. injection of JMV 2959 at 1, 3, and 6 mg/kg reduces ASR and enhances PPI in a dose-dependent manner. While JMV 2959 at a non-effective dose on its own prevents PPI deficits induced by Phencyclidine (PCP) at 2 mg/kg, pre-administration of the highest dose of Ghrelin does not alter PPI responses to a sub-threshold dose of PCP (0.75 mg/kg). |
| Synonyms | JMV 2959 hydrochloride |
| Molecular Weight | 545.08 |
| Formula | C30H33ClN6O2 |
| Cas No. | 2448414-54-6 |
| Smiles | COC1=CC=C(CN2C(CCC3=CC=CC=C3)=NN=C2[C@H](NC(CN)=O)CC4=CNC5=CC=CC=C54)C=C1.Cl |
| Storage | Pure form: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 250 mg/mL (458.65 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 3.3 mg/mL (6.05 mM), Sonication is recommeded. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.